Murphy & Mullick Capital Management Corp Astrazeneca PLC Transaction History
Murphy & Mullick Capital Management Corp
- $109 Billion
- Q4 2024
A detailed history of Murphy & Mullick Capital Management Corp transactions in Astrazeneca PLC stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 4,059 shares of AZN stock, worth $295,211. This represents 0.25% of its overall portfolio holdings.
Number of Shares
4,059Holding current value
$295,211% of portfolio
0.25%Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,344Shares Held
478MCall Options Held
5.39MPut Options Held
3.79M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.57 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$2.98 Billion2.12% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.69 Billion0.46% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.68 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.5MShares$1.42 Billion0.37% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $225B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...